Journalartikel
Autorenliste: Guler, Sabina; Sarbu, Adela-Cristina; Stalder, Odile; Allanore, Yannick; Bernardino, Vera; Distler, Joerg; Gabrielli, Armando; Hoffmann-Vold, Anna-Maria; Matucci-Cerinic, Marco; Mueller-Ladner, Ulf; Ortiz-Santamaria, Vera; Rednic, Simona; Riccieri, Valeria; Smith, Vanessa; Ullman, Susanne; Walker, Ulrich A.; Geiser, Thomas K.; Distler, Oliver; Maurer, Britta; Kollert, Florian
Jahr der Veröffentlichung: 2023
Seiten: 1188-1196
Zeitschrift: Thorax
Bandnummer: 78
Heftnummer: 12
ISSN: 0040-6376
eISSN: 1468-3296
DOI Link: https://doi.org/10.1136/thorax-2023-220541
Verlag: BMJ Publishing Group
Abstract:
Background Systemic sclerosis (SSc) is a heterogeneous disease with frequently associated interstitial lung disease (SSc-ILD). We aimed to determine the prognostic potential of phenotyping patients with SSc and SSc-ILD by inflammation and to describe disease trajectories stratified by inflammation and immunosuppressive treatment.Methods Patients from the European Scleroderma Trials and Research (EUSTAR) group cohort were allocated to persistent inflammatory, intermediate and non-inflammatory phenotypes if C-reactive protein (CRP) levels were >= 5 mg/L at >= 80%, at 20-80% and at <20% of visits, respectively. Cox regression models were used to analyse mortality risk and mixed effect models to describe trajectories of FVC and diffusing capacity for carbon monoxide (DLCO) %-predicted stratified by inflammation and immunosuppressive treatment.Results 2971 patients with SSc and 1171 patients with SSc-ILD had at least three CRP measurements available. Patients with SSc-ILD with a persistent inflammatory phenotype had a 6.7 times higher risk of mortality within 5 years compared with those with a persistent non-inflammatory phenotype (95% CI 3 to 15). In the inflammatory phenotype, FVC %-predicted was declining without (-1.11 (95% CI -2.14 to -0.08)/year), but stable with immunosuppressive treatment (-0.00 (95% CI -0.92 to 0.92)/year). In the non-inflammatory phenotype, patients with and without immunosuppressive treatment had a significant decline in FVC %-predicted, which was more pronounced in those with immunosuppressive treatment (-1.26 (95% CI -1.87 to -0.64) and -0.84 (95% CI -1.35 to -0.33)/year, respectively).Conclusions Phenotyping by persistent inflammation provides valuable prognostic information, independent of demographics, disease duration, cutaneous subtype, treatment and SSc-ILD severity. The findings from this study support early immunosuppressive treatment in patients with SSc-ILD with persistent inflammation.
Zitierstile
Harvard-Zitierstil: Guler, S., Sarbu, A., Stalder, O., Allanore, Y., Bernardino, V., Distler, J., et al. (2023) Phenotyping by persistent inflammation in systemic sclerosisassociated interstitial lung disease: a EUSTAR database analysis, Thorax, 78(12), pp. 1188-1196. https://doi.org/10.1136/thorax-2023-220541
APA-Zitierstil: Guler, S., Sarbu, A., Stalder, O., Allanore, Y., Bernardino, V., Distler, J., Gabrielli, A., Hoffmann-Vold, A., Matucci-Cerinic, M., Mueller-Ladner, U., Ortiz-Santamaria, V., Rednic, S., Riccieri, V., Smith, V., Ullman, S., Walker, U., Geiser, T., Distler, O., Maurer, B., ...Kollert, F. (2023). Phenotyping by persistent inflammation in systemic sclerosisassociated interstitial lung disease: a EUSTAR database analysis. Thorax. 78(12), 1188-1196. https://doi.org/10.1136/thorax-2023-220541
Schlagwörter
CYCLOPHOSPHAMIDE; DOUBLE-BLIND; EULAR SCLERODERMA TRIALS; Interstitial Fibrosis; PLACEBO; PULMONARY-FUNCTION; Rheumatoid lung disease; SCLEROSIS; Systemic disease and lungs
